These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 30345007

  • 1. Recent trends in the management of advanced prostate cancer.
    Ritch C, Cookson M.
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [Abstract] [Full Text] [Related]

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 3. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 4. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S, Carlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, Aschelter AM, Felici A, Valeriani M, Cognetti F, Marchetti P.
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [Abstract] [Full Text] [Related]

  • 5. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C, Jimeno A, Kessler ER.
    Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
    [Abstract] [Full Text] [Related]

  • 6. Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.
    Fukuokaya W, Mori K, Yanagisawa T, Akazawa K, Shimomura T, Kimura T.
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):444-450. PubMed ID: 37464102
    [Abstract] [Full Text] [Related]

  • 7. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A, Hussain M.
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [Abstract] [Full Text] [Related]

  • 8. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z, Saad F, Fizazi K.
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [Abstract] [Full Text] [Related]

  • 9. The importance of targeting intracrinology in prostate cancer management.
    Hamid ARAH, Tendi W, Sesari SS, Mochtar CA, Umbas R, Verhaegh G, Schalken JA.
    World J Urol; 2019 May; 37(5):751-757. PubMed ID: 30350016
    [Abstract] [Full Text] [Related]

  • 10. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
    Caffo O, Veccia A, Kinspergher S, Maines F.
    Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [Abstract] [Full Text] [Related]

  • 12. Abiraterone acetate in the treatment of prostate cancer.
    Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S.
    Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
    [Abstract] [Full Text] [Related]

  • 13. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F, Fizazi K.
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Koizumi A, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nomura K, Habuchi T.
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [Abstract] [Full Text] [Related]

  • 15. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
    Ohlmann CH, Goebell PJ, Grimm MO, Klier J, König F, Machtens S, Schostak M, Schrader AJ, Albers P.
    Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
    [Abstract] [Full Text] [Related]

  • 16. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
    Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J.
    Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616
    [Abstract] [Full Text] [Related]

  • 17. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
    Wang L, Hong H, Alexander GC, Brawley OW, Paller CJ, Ballreich J.
    Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
    [Abstract] [Full Text] [Related]

  • 18. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C, Mourey L, Pouessel D, Ploussard G.
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [Abstract] [Full Text] [Related]

  • 19. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G, Chen X, Gong U, Chen Y, Li G, Wei F, Jiang A, Niu Y, Shang Z.
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [Abstract] [Full Text] [Related]

  • 20. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ.
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.